# Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

Source: https://onco.cc/key-papers/paper-relativity-047-nejm-evid-2023-update/  
OnCo record `paper-relativity-047-nejm-evid-2023-update` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Later report from the RELATIVITY-047 trial registered as NCT03470922, in NEJM Evidence (2023); its title describes an updated or longer-term analysis.

## Summary

BACKGROUND: A phase 2/3 trial, A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047), evaluated nivolumab + relatlimab as a fixed-dose combination and found a significant progression-free survival (PFS) benefit over nivolumab monotherapy in previously untreated unresectable or metastatic melanoma. We now report updated PFS and safety data and the first results for overall survival (OS) and objective response rate (ORR). METHODS: Patients were randomly assigned 1:1 to receive nivolumab 480 mg and relatlimab 160 mg fixed-dose combination or nivolumab 480 mg alone, given intravenously every 4 weeks. PFS (primary end point) according to the Response Evaluation Criteria in Solid Tumors, version 1.1, was assessed by blinded independent central review (BICR). Secondary end points, tested hierarchically, were OS and then ORR per Response Evaluation Criteria in Solid Tumors, version 1.1, per BICR. RESULTS: At a median follow-up of 19.3 months, median PFS according to BICR was 10.2 months (95% confidence interval [CI], 6.5 to 14.8) with nivolumab + relatlimab versus 4.6 months (95% CI, 3.5 to 6.4) with nivolumab (hazard ratio, 0.78; 95% CI, 0.64 to 0.94). Median OS was not reached (NR) (95% CI, 34.2 to NR) with nivolumab + relatlimab versus 34.1 months (95% CI, 25.2 to NR) with nivolumab (hazard ratio, 0.80; 95% CI, 0.64 to 1.01; P=0.059) (prespecified value for statistical significance, P≤0.043). ORRs per BICR were 43.1% (95% CI, 37.9 to 48.4) versus 32.6% (95% CI, 27.8 to 37.7), respectively. Grade 3/4 treatment-related adverse events were observed in 21.1% of patients treated with nivolumab + relatlimab versus 11.1% treated with nivolumab. CONCLUSIONS: The fixed-dose combination of nivolumab + relatlimab showed consistent PFS benefit versus nivolumab with approximately 6 months of additional median follow-up. The combination treatment did not reach the preplanned statistical threshold for OS, with a 10.3 percentage-point difference in ORR. Grade 3/4 treatment-related adverse events were more frequent with nivolumab + relatlimab versus nivolumab. (Funded by Bristol Myers Squibb; ClinicalTrials.gov number, NCT03470922.)

Indexed on Europe PMC as PubMed record 38320023 (DOI 10.1056/evidoa2200239). Its abstract cites the registry id NCT03470922, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: NEJM Evidence
- Year: 2023
- DOI: 10.1056/evidoa2200239
- Authors: Long GV, Stephen Hodi F, Lipson EJ, et al.
- What it means: A second publication from the RELATIVITY-047 trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; Chosen as a later report by words in its title (updated, long-term, final, overall survival or a year count), not by reading the paper.

## Sources

- NEJM Evid 2023: https://doi.org/10.1056/evidoa2200239
- PubMed: https://pubmed.ncbi.nlm.nih.gov/38320023/
- Europe PMC: https://europepmc.org/article/MED/38320023
- ClinicalTrials.gov NCT03470922: https://clinicaltrials.gov/study/NCT03470922

## Connected records

- trials: [RELATIVITY-047](https://onco.cc/trials/relativity-047/)
- journals: [NEJM Evidence](https://onco.cc/journals/nejm-evidence/)

---
JSON: https://onco.cc/api/v1/entities/paper-relativity-047-nejm-evid-2023-update.json